SHABARI GIRINATH KALA
Olmesartan medoxomil (OM) is employed for treating patients who are intolerant of ACE inhibitors. The challenge to the researchers is because of its poor oral bioavailability and poor solubility. The approach for this problem is to use a hydrophilic carrier in formulation of oro-dispersible tablet (ODT) which presents a suitable way to improve the bioavailability by using quality by design (QbD) techniques with design of experiments (DoE) which produce a robust and rugged formulation.
The focus of the research was to formulate OM/PVP solid dispersion (SD) and formulation of an Oro dispersible tablet (ODT) by QbD techniques. The main focus of this research is to provide a rugged and robust formulation using QbD concept with the application of Definitive screening design for optimization.
The dissolution studies of OM/PVP K30 1:1% w/w showed full release within 30 min which may be attributed due to the hydrogen bond formation between OM and PVP K30 in the FTIR spectra which enhanced the solubility. The present research highlights a thorough understanding of the dosage form development with the knowledge of the critical risks involved in formulation to have an impact on Critical Quality Attributes (CQAs). The Critical material attributes (CMAs) were refined by DoE using definitive screening design (DSD) to develop design space
